CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-02 | Gollob Jared Chief Medical Officer | Sale | −297 | $31.40 | $9K | 74,709 |
| 2023-03-02 | Jacobs Bruce N. Chief Financial Officer | Sale | −1,056 | $30.88 | $33K | 104,882 |
| 2023-03-02 | Jacobs Bruce N. Chief Financial Officer | Sale | −314 | $31.40 | $10K | 104,568 |
| 2023-03-01 | Mainolfi Nello Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2023-03-01 | Caughey Elaine Chief Business Officer | Grant or award | +10,557 | 19,700 | ||
| 2023-03-01 | Caughey Elaine Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +63,338 | 63,338 | ||
| 2023-03-01 | Gollob Jared Chief Medical Officer | Grant or award | +18,750 | 76,007 | ||
| 2023-03-01 | Gollob Jared Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2023-03-01 | Jacobs Bruce N. Chief Financial Officer | Grant or award | +23,750 | 105,938 | ||
| 2023-03-01 | Jacobs Bruce N. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +142,500 | 142,500 | ||
| 2023-01-12 | Booth Bruce Director | Sale | −77,128 | $30.29 | $2.3M | 4,968,114 |
| 2023-01-12 | Booth Bruce Director | Sale | −21,592 | $30.29 | $654K | 890,148 |
| 2023-01-12 | Atlas Venture Fund X, L.P. 10% owner | Sale | −77,128 | $30.29 | $2.3M | 4,968,114 |
| 2023-01-12 | Atlas Venture Fund X, L.P. 10% owner | Sale | −21,592 | $30.29 | $654K | 890,148 |
| 2023-01-12 | BVF PARTNERS L P/IL Director | Purchase | +2,985 | $31.24 | $93K | 2,494,688 |
| 2023-01-12 | BVF PARTNERS L P/IL Director | Purchase | +15,912 | $31.24 | $497K | 1,888,351 |
| 2023-01-11 | Booth Bruce Director | Sale | −21,683 | $29.96 | $650K | 5,045,242 |
| 2023-01-11 | Booth Bruce Director | Sale | −6,071 | $29.96 | $182K | 911,740 |
| 2023-01-11 | Atlas Venture Fund X, L.P. 10% owner | Sale | −21,683 | $29.96 | $650K | 5,045,242 |
| 2023-01-11 | Atlas Venture Fund X, L.P. 10% owner | Sale | −6,071 | $29.96 | $182K | 911,740 |
Page 33 of 41 · 810 trades